RS60411B1 - Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida - Google Patents

Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Info

Publication number: RS60411B1
Authority: RS; Serbia
Prior art keywords: ynoyl; pyrazin; imidazo; pyrrolidin; benzamide
Prior art date: 2015-07-02

Application number

RS20200681A

Other languages

English (en)

Inventor

Fritz Blatter

Tim Ingallinera

Tjeerd Barf

Edwin Aret

Cecile Krejsa

Jerry Evarts

Original Assignee

Acerta Pharma Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-02

Filing date

2016-07-01

Publication date

2020-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60411(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-01 Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv

2020-07-31 Publication of RS60411B1 publication Critical patent/RS60411B1/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

RS20200681A 2015-07-02 2016-07-01 Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida RS60411B1 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562188468P	2015-07-02	2015-07-02
US201562271708P	2015-12-28	2015-12-28
EP16735945.4A EP3317281B1 (en)	2015-07-02	2016-07-01	Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
PCT/IB2016/053988 WO2017002095A1 (en)	2015-07-02	2016-07-01	Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number	Publication Date
RS60411B1 true RS60411B1 (sr)	2020-07-31

Family

ID=56363881

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
RS20211291A RS62455B1 (sr)	2015-07-02	2016-07-01	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
RS20200681A RS60411B1 (sr)	2015-07-02	2016-07-01	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
RS20230367A RS64195B1 (sr)	2015-07-02	2016-07-01	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
RS20211291A RS62455B1 (sr)	2015-07-02	2016-07-01	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20230367A RS64195B1 (sr)	2015-07-02	2016-07-01	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Country Status (29)

Country	Link
US (6)	US9796721B2 (sr)
EP (4)	EP3954690B1 (sr)
JP (3)	JP6829215B2 (sr)
KR (1)	KR20180048593A (sr)
CN (2)	CN113480542A (sr)
AU (3)	AU2016286548B2 (sr)
CA (1)	CA2991096A1 (sr)
CL (1)	CL2017003445A1 (sr)
CY (3)	CY1124519T1 (sr)
DK (3)	DK3613745T3 (sr)
ES (3)	ES2895802T3 (sr)
FI (1)	FI3954690T3 (sr)
HK (1)	HK1250511A1 (sr)
HR (3)	HRP20211511T1 (sr)
HU (3)	HUE049989T2 (sr)
IL (3)	IL274066B (sr)
LT (3)	LT3613745T (sr)
MA (1)	MA50817B1 (sr)
MD (1)	MD3317281T2 (sr)
MX (2)	MX2018000179A (sr)
MY (1)	MY193514A (sr)
PL (3)	PL3317281T3 (sr)
PT (3)	PT3613745T (sr)
RS (3)	RS62455B1 (sr)
RU (1)	RU2018103913A (sr)
SG (1)	SG10201913796UA (sr)
SI (3)	SI3317281T1 (sr)
WO (1)	WO2017002095A1 (sr)
ZA (2)	ZA201800329B (sr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20211813T1 (hr) *	2014-08-11	2022-03-04	Acerta Pharma B.V.	Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
ES2895802T3 (es)	2015-07-02	2022-02-22	Acerta Pharma Bv	Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
US10899767B2 (en) *	2016-10-05	2021-01-26	Hangzhou Solipharma Co., Ltd.	Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
WO2018115965A1 (en) *	2016-12-23	2018-06-28	Acerta Pharma Bv	Solid forms of imidazopyrazine compounds
CN110312723B (zh) *	2017-02-20	2022-02-11	杭州领业医药科技有限公司	Acp-196盐的晶型、其制备方法、药物组合物和用途
CN110709083A (zh) *	2017-03-27	2020-01-17	特沙诺有限公司	尼拉帕尼制剂
TWI761476B (zh)	2017-03-27	2022-04-21	美商提薩羅有限公司	尼拉帕尼(niraparib)組合物
US10717740B2 (en)	2017-06-13	2020-07-21	Dr. Reddy's Laboratories Limited.	Solid forms of acalabrutinib and process for preparation thereof
CA3073293A1 (en)	2017-08-29	2019-03-07	Apotex Inc.	Novel crystalline forms of acalabrutinib
SG11202002113TA (en)	2017-09-26	2020-04-29	Tesaro Inc	Niraparib formulations
WO2019105359A1 (zh) *	2017-11-30	2019-06-06	苏州科睿思制药有限公司	Acalabrutinib的晶型及其制备方法和用途
KR20200106511A (ko) *	2018-01-05	2020-09-14	크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디.	아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019159097A1 (en) *	2018-02-14	2019-08-22	Sun Pharmaceutical Industries Limited	Crystalline polymorphic forms of acalabrutinib
US20210087195A1 (en) *	2018-04-26	2021-03-25	Crystal Pharmaceutical (Suzhou) Co., Ltd.	New crystal form of acalbrutinib, preparation method therefor and use thereof
EP3587421A1 (en)	2018-06-29	2020-01-01	Sandoz AG	Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
WO2020053795A2 (en)	2018-09-13	2020-03-19	Fresenius Kabi Oncology Ltd.	Process for the preparation of acalabrutinib and its intermediates
EP3830091A1 (en)	2018-09-25	2021-06-09	Cipla Limited	Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2020198429A1 (en)	2019-03-27	2020-10-01	Assia Chemical Industries Ltd	Solid state forms of acalabrutinib
WO2020225831A1 (en) *	2019-05-09	2020-11-12	Msn Laboratories Private Limited, R&D Center	Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (zh) *	2019-12-31	2021-07-08	苏州科睿思制药有限公司	Acalabrutinib的新晶型及其制备方法和用途
WO2021239893A1 (en)	2020-05-29	2021-12-02	Bend Research, Inc.	Amorphous solid dispersion of acalabrutinib
CR20230018A (es)	2020-06-19	2023-04-11	Acerta Pharma Bv	Formas farmacéuticas de maleato de acalabrutinib
CN112028896A (zh) *	2020-10-14	2020-12-04	奥锐特药业(天津)有限公司	阿卡替尼的新晶型及其制备方法
WO2022153330A1 (en) *	2021-01-13	2022-07-21	Natco Pharma Limited	Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en)	2021-08-03	2023-02-09	Syros Pharmaceuticals, Inc.	Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) *	2022-04-19	2023-10-26	The Johns Hopkins University	Improved raman spectroscopy with the addition of aromatic compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001081031A (ja)	1999-08-30	2001-03-27	Schering Ag	溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
DE60037455T2 (de)	1999-09-17	2008-11-27	Abbott Gmbh & Co. Kg	Kinaseinhibitoren als arzneimittel
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
CN1898240B (zh)	2003-10-15	2011-08-03	Osi制药公司	咪唑并吡嗪类酪氨酸激酶抑制剂
CA2561950C (en)	2004-04-02	2010-04-20	Osi Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
ITMI20051231A1 (it)	2005-06-29	2006-12-30	Pharmaproducts Uk Ltd	Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
WO2007048220A2 (en)	2005-09-09	2007-05-03	Labopharm Inc.	Trazodone composition for once a day adminisitiation
ES2436877T3 (es)	2005-11-17	2014-01-07	OSI Pharmaceuticals, LLC	Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007106503A2 (en)	2006-03-13	2007-09-20	Osi Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
SI2526934T1 (sl)	2006-09-22	2016-04-29	Pharmacyclics Llc	Inhibitorji Bruton tirozin kinaze
US8809273B2 (en)	2007-03-28	2014-08-19	Pharmacyclics, Inc.	Inhibitors of Bruton's tyrosine kinase
EP2561875A3 (en)	2007-03-28	2013-06-12	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) *	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
RU2010128239A (ru)	2007-12-13	2012-01-20	Новартис АГ (CH)	Комбинации терапевтических средств, предназначенных для лечения рака
US9095592B2 (en)	2008-11-07	2015-08-04	The Research Foundation For The State University Of New York	Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (en)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
WO2011095556A1 (en)	2010-02-08	2011-08-11	N.V. Organon	8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
CN102190594A (zh) *	2010-03-17	2011-09-21	上海医药工业研究院	阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es)	2010-03-25	2011-10-31	Glaxosmithkline Llc	Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI535716B (zh)	2010-05-31	2016-06-01	Ono Pharmaceutical Co	Purine ketone derivatives
MX342405B (es)	2010-06-03	2016-09-28	Pharmacyclics Inc	El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120053189A1 (en)	2010-06-28	2012-03-01	Pharmacyclics, Inc.	Btk inhibitors for the treatment of immune mediated conditions
US9580427B2 (en)	2011-05-17	2017-02-28	The Regents Of The University Of California	Kinase inhibitors
WO2013003629A2 (en)	2011-06-28	2013-01-03	Pharmacyclics, Inc.	Methods and compositions for inhibition of bone resorption
BR112014000653A2 (pt)	2011-07-13	2017-02-14	Pharmacyclics Inc	inibidores de tirosina quinase de bruton
EP2548877A1 (en) *	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014522860A (ja)	2011-07-19	2014-09-08	メルク・シャープ・アンド・ドーム・ベー・フェー	Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
DK2734522T3 (en)	2011-07-19	2019-02-18	Merck Sharp & Dohme	4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
JP6506555B2 (ja)	2011-10-19	2019-04-24	ファーマサイクリックスエルエルシー	ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US20140212425A1 (en)	2011-12-05	2014-07-31	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9481682B2 (en)	2013-01-23	2016-11-01	Merck Sharp & Dohme Corp.	Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
CN105073115A (zh)	2013-03-14	2015-11-18	药品循环有限责任公司	布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014143807A2 (en)	2013-03-15	2014-09-18	Stromatt Scott	Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
EA031493B9 (ru)	2013-04-08	2019-12-18	Байер Фарма Акциенгезельшафт	Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
JP6575952B2 (ja)	2013-04-08	2019-09-18	ファーマサイクリックスエルエルシー	イブルチニブ併用療法
WO2015018522A1 (en)	2013-08-06	2015-02-12	Oncoethix Sa	Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) *	2013-10-16	2015-04-23	Izumi Raquel	Btk inhibitors for hematopoietic mobilization
US10328080B2 (en)	2013-12-05	2019-06-25	Acerta Pharma, B.V.	Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2015086642A1 (en)	2013-12-13	2015-06-18	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
WO2015110923A2 (en)	2014-01-21	2015-07-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (fr)	2014-06-02	2016-05-13	Morpho	Procede de validation de l'authenticite d'un element du corps humain
ES2895802T3 (es)	2015-07-02	2022-02-22	Acerta Pharma Bv	Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida

2016
- 2016-07-01 ES ES19196939T patent/ES2895802T3/es active Active
- 2016-07-01 PT PT191969393T patent/PT3613745T/pt unknown
- 2016-07-01 HU HUE16735945A patent/HUE049989T2/hu unknown
- 2016-07-01 MD MDE20180479T patent/MD3317281T2/ro unknown
- 2016-07-01 LT LTEP19196939.3T patent/LT3613745T/lt unknown
- 2016-07-01 LT LTEP16735945.4T patent/LT3317281T/lt unknown
- 2016-07-01 PL PL16735945T patent/PL3317281T3/pl unknown
- 2016-07-01 SI SI201630805T patent/SI3317281T1/sl unknown
- 2016-07-01 RU RU2018103913A patent/RU2018103913A/ru unknown
- 2016-07-01 LT LTEP21182842.1T patent/LT3954690T/lt unknown
- 2016-07-01 CN CN202110761102.5A patent/CN113480542A/zh active Pending
- 2016-07-01 EP EP21182842.1A patent/EP3954690B1/en active Active
- 2016-07-01 KR KR1020187003310A patent/KR20180048593A/ko not_active Application Discontinuation
- 2016-07-01 JP JP2017568182A patent/JP6829215B2/ja active Active
- 2016-07-01 DK DK19196939.3T patent/DK3613745T3/da active
- 2016-07-01 ES ES16735945T patent/ES2797987T3/es active Active
- 2016-07-01 HR HRP20211511TT patent/HRP20211511T1/hr unknown
- 2016-07-01 HU HUE21182842A patent/HUE062258T2/hu unknown
- 2016-07-01 EP EP19196939.3A patent/EP3613745B1/en active Active
- 2016-07-01 PL PL21182842.1T patent/PL3954690T3/pl unknown
- 2016-07-01 DK DK21182842.1T patent/DK3954690T3/da active
- 2016-07-01 EP EP23157244.7A patent/EP4209493A1/en active Pending
- 2016-07-01 IL IL274066A patent/IL274066B/en unknown
- 2016-07-01 DK DK16735945.4T patent/DK3317281T3/da active
- 2016-07-01 HU HUE19196939A patent/HUE056008T2/hu unknown
- 2016-07-01 PT PT167359454T patent/PT3317281T/pt unknown
- 2016-07-01 IL IL293821A patent/IL293821A/en unknown
- 2016-07-01 AU AU2016286548A patent/AU2016286548B2/en active Active
- 2016-07-01 CN CN201680050713.6A patent/CN108349978B/zh active Active
- 2016-07-01 MX MX2018000179A patent/MX2018000179A/es unknown
- 2016-07-01 MA MA50817A patent/MA50817B1/fr unknown
- 2016-07-01 HR HRP20230417TT patent/HRP20230417T1/hr unknown
- 2016-07-01 RS RS20211291A patent/RS62455B1/sr unknown
- 2016-07-01 RS RS20200681A patent/RS60411B1/sr unknown
- 2016-07-01 SI SI201631705T patent/SI3954690T1/sl unknown
- 2016-07-01 PL PL19196939T patent/PL3613745T3/pl unknown
- 2016-07-01 RS RS20230367A patent/RS64195B1/sr unknown
- 2016-07-01 WO PCT/IB2016/053988 patent/WO2017002095A1/en active Application Filing
- 2016-07-01 CA CA2991096A patent/CA2991096A1/en active Pending
- 2016-07-01 PT PT211828421T patent/PT3954690T/pt unknown
- 2016-07-01 MY MYPI2017001918A patent/MY193514A/en unknown
- 2016-07-01 FI FIEP21182842.1T patent/FI3954690T3/fi active
- 2016-07-01 SI SI201631364T patent/SI3613745T1/sl unknown
- 2016-07-01 SG SG10201913796UA patent/SG10201913796UA/en unknown
- 2016-07-01 US US15/200,875 patent/US9796721B2/en active Active
- 2016-07-01 ES ES21182842T patent/ES2946489T3/es active Active
- 2016-07-01 EP EP16735945.4A patent/EP3317281B1/en active Active
- 2016-07-01 MX MX2020014163A patent/MX2020014163A/es unknown
2017
- 2017-09-18 US US15/707,508 patent/US10167291B2/en active Active
- 2017-12-28 IL IL256633A patent/IL256633B/en active IP Right Grant
- 2017-12-28 CL CL2017003445A patent/CL2017003445A1/es unknown
2018
- 2018-01-17 ZA ZA2018/00329A patent/ZA201800329B/en unknown
- 2018-07-31 HK HK18109886.8A patent/HK1250511A1/zh unknown
- 2018-11-01 US US16/177,927 patent/US10640509B2/en active Active
2020
- 2020-01-16 ZA ZA2020/00300A patent/ZA202000300B/en unknown
- 2020-04-30 US US16/863,033 patent/US11059829B2/en active Active
- 2020-06-10 HR HRP20200934TT patent/HRP20200934T1/hr unknown
- 2020-07-02 CY CY20201100611T patent/CY1124519T1/el unknown
- 2020-11-24 AU AU2020277123A patent/AU2020277123B2/en active Active
2021
- 2021-01-21 JP JP2021007689A patent/JP7091494B2/ja active Active
- 2021-06-10 US US17/344,233 patent/US20220177476A1/en not_active Abandoned
- 2021-10-19 CY CY20211100904T patent/CY1124815T1/el unknown
2022
- 2022-01-27 US US17/586,726 patent/US11820777B2/en active Active
- 2022-06-15 JP JP2022096907A patent/JP2022120156A/ja active Pending
- 2022-12-23 AU AU2022291635A patent/AU2022291635A1/en active Pending
2023
- 2023-06-01 CY CY20231100260T patent/CY1126103T1/el unknown

Also Published As

Publication number	Publication date
EP4209493A1 (en)	2023-07-12
SG10201913796UA (en)	2020-03-30
AU2022291635A1 (en)	2023-02-02
SI3317281T1 (sl)	2020-08-31
EP3317281A1 (en)	2018-05-09
US20220348582A1 (en)	2022-11-03
AU2020277123A1 (en)	2020-12-24
LT3613745T (lt)	2021-10-11
US11059829B2 (en)	2021-07-13
DK3613745T3 (da)	2021-10-18
CY1126103T1 (el)	2023-11-15
RS64195B1 (sr)	2023-06-30
EP3613745A1 (en)	2020-02-26
AU2016286548B2 (en)	2020-12-10
HUE049989T2 (hu)	2020-11-30
LT3317281T (lt)	2020-07-27
MA50817B1 (fr)	2021-10-29
US11820777B2 (en)	2023-11-21
US20190337949A1 (en)	2019-11-07
JP7091494B2 (ja)	2022-06-27
PL3317281T3 (pl)	2020-11-02
MX2018000179A (es)	2018-06-27
JP6829215B2 (ja)	2021-02-10
ES2797987T3 (es)	2020-12-04
US20170029428A1 (en)	2017-02-02
US10167291B2 (en)	2019-01-01
PL3613745T3 (pl)	2022-01-31
MY193514A (en)	2022-10-17
US9796721B2 (en)	2017-10-24
SI3954690T1 (sl)	2023-07-31
US10640509B2 (en)	2020-05-05
AU2016286548A1 (en)	2018-02-01
KR20180048593A (ko)	2018-05-10
CA2991096A1 (en)	2017-01-05
PT3317281T (pt)	2020-06-18
SI3613745T1 (sl)	2021-12-31
EP3613745B1 (en)	2021-09-01
HRP20211511T1 (hr)	2021-12-24
HUE062258T2 (hu)	2023-10-28
JP2021073235A (ja)	2021-05-13
RU2018103913A (ru)	2019-08-02
HUE056008T2 (hu)	2022-01-28
FI3954690T3 (fi)	2023-05-31
ES2946489T3 (es)	2023-07-19
CN108349978B (zh)	2021-07-23
EP3954690A1 (en)	2022-02-16
CN113480542A (zh)	2021-10-08
CY1124815T1 (el)	2022-11-25
CN108349978A (zh)	2018-07-31
PT3954690T (pt)	2023-06-06
JP2018522877A (ja)	2018-08-16
HRP20230417T1 (hr)	2023-07-07
LT3954690T (lt)	2023-05-25
CL2017003445A1 (es)	2018-05-11
ES2895802T3 (es)	2022-02-22
IL274066A (en)	2020-06-30
AU2020277123B2 (en)	2022-09-29
EP3954690B1 (en)	2023-04-05
WO2017002095A1 (en)	2017-01-05
US20200255437A1 (en)	2020-08-13
EP3317281B1 (en)	2020-04-22
CY1124519T1 (el)	2022-03-24
HK1250511A1 (zh)	2018-12-21
IL293821A (en)	2022-08-01
RU2018103913A3 (sr)	2019-12-31
ZA202000300B (en)	2022-03-30
HRP20200934T1 (hr)	2020-09-18
PL3954690T3 (pl)	2023-08-14
IL274066B (en)	2022-07-01
RS62455B1 (sr)	2021-11-30
IL256633A (en)	2018-02-28
PT3613745T (pt)	2021-10-14
DK3317281T3 (da)	2020-06-15
ZA201800329B (en)	2022-04-28
JP2022120156A (ja)	2022-08-17
US20220177476A1 (en)	2022-06-09
DK3954690T3 (da)	2023-06-06
MX2020014163A (es)	2022-09-29
MD3317281T2 (ro)	2020-07-31
IL256633B (en)	2020-05-31
MA50817A (fr)	2021-04-21
US20180208596A1 (en)	2018-07-26

Publication	Publication Date	Title
IL274066A (en)	2020-06-30	Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
IL290905A (en)	2022-04-01	Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
IL262964B (en)	2021-06-30	Preparation of (s)-n-(5-((r)-2-(5,2-difluorophenyl)pyrrolidine-1-yl)pyrazolo[5,1-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide and their salts
IL262003A (en)	2018-10-31	Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide